Endocrinology of the Menopause

Hall, Janet E.

doi:10.1016/j.ecl.2015.05.010

Cited by 138 publications

(89 citation statements)

References 93 publications

(79 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anatomical changes in ovary due to aging process selectively occur in females with menopause such as vascular sclerosis, decreasing amount of primordial follicle, and decreasing activity of steroid hormone synthesize. The low level of estrogen can cause 3,6 disturbances of its physiological function.…”

Section: Pathophysiology Of Menopause the Decline Of Ovary Function Imentioning

confidence: 99%

“…Inhibin B is a hormone measured in the transition phase of early menopause (around 5 years before menopause), about 41% not detected in two years before menopause and 71% not detected in one year 6,10 before menopause (menopause transition end).…”

Section: Inhibin Bmentioning

confidence: 99%

“…Indonesian Journal of Clinical Pathology and Medical Laboratory, 2019 March, 25 (2) : 233 -239 between reproductive and period, the peak level of estradiol secretion in menstrual until post-menopause period may not decrease. There is no estradiol cut-off point to predict the time of menopause transition phase or menopause 6,7 period.…”

Section: Page 239mentioning

confidence: 99%

See 2 more Smart Citations

Hormone Examination in Menopause

Marpaung

Butarbutar

Soehita

2019

Indonesian J. Clin. Pathol. Med. Lab.

View full text Add to dashboard Cite

World Health Organization (WHO) and Stages of Reproductive Aging Workshop (STRAW) define menopause as a permanent end point of menstrual cycle that occurs naturally or by induction of surgical procedure, chemotherapy, or radiation. Clinically, menopause involved women over 40 or 50 years old. Approximately, fifty million women in the world is experiencing menopause annually. The etiology of menopause is classified into physiologic and non-physiologic. Pathophysiology of menopause includes decline of ovary function in menopause, response to loss of ovarian feedback mechanism, decline of hypothalamus and pituitary function. Endocrine changes in menopause lead to alteration of gonadotropin secretion cycle patterns, changes in steroid and peptide hormones through monophasic patterns to increase gonadotropin, decrease of estrogen, progesterone and inhibin. Clinical symptoms of menopause or estrogen deficiency syndrome classified into short term clinical symptoms and long term clinical symptoms. Hormonal examination in menopause consist of Follicular Stimulating Hormone (FSH), Anti-Mullerian Hormone (AMH), Luteinizing Hormone (LH), Inhibin B and Estradiol. The important of time to examine the hormones should be considered carefully.

show abstract

Section: Pathophysiology Of Menopause the Decline Of Ovary Function Imentioning

confidence: 99%

Section: Inhibin Bmentioning

confidence: 99%

See 1 more Smart Citation

Hormone Examination in Menopause

Marpaung

Butarbutar

Soehita

2019

Indonesian J. Clin. Pathol. Med. Lab.

View full text Add to dashboard Cite

show abstract

“…Resultant changes in hypothalamic and pituitary hormones to compensate for the falling reserve of ovarian follicles maintain ovulation and fertility, sometimes for decades. The transition to the menopausal state demonstrates highly variable cyclic follicle development and ovulation, along with disrupted menstrual bleeding patterns 1 . The average at menopause is about 51 with later age of menopause correlating with longevity 2–4 .…”

Section: Introductionmentioning

confidence: 99%

Menopause and Rheumatic Disease

Talsania

Scofield

2017

Rheumatic Disease Clinics of North America

View full text Add to dashboard Cite

Abstract/Synopsis Menopause occurs naturally in women at about age 50. There is a wealth of data concerning the relationship of menopause to systemic lupus erythematosus, rheumatoid arthritis and osteoarthritis, while there are limited data concerning other rheumatic diseases. Age at menopause may affect the risk and course of rheumatic diseases. Osteoporosis, an integral part of inflammatory rheumatic diseases, is made worse by menopause. Hormone replacement therapy has been studied and its effects are varied depending upon the disease and even different manifestations within the same disease. Cyclophosphamide can induce early menopause but there is underlying decreased ovarian reserve in rheumatic diseases.

show abstract

“…In women, the closure of reproductive life is known as menopause, which is characterized by permanent cessation of menstruation due to loss of ovarian function (Greendale, Lee, & Arriola, 1999;Hall, 2015;Nelson, 2008). Females after the 40 years of age generally report menopause symptoms, such as heat waves, mood alteration and low libido, which are secondary to oestrogen levels decline and a part of the natural ageing process (Hall, 2015;Nikolaou & Gilling-Smith, 2004;Walsh & Schiff, 2001).…”

mentioning

confidence: 99%

Sex hormone replacement therapy in periodontology—A systematic review

et al. 2019

View full text Add to dashboard Cite

Objective To analyse whether sex hormone replacement therapy (HRT) improves periodontal parameters and dental implants osseointegration in humans. Materials and Methods Electronic databases and hand searches were performed from June to August 2018 in SciELO, LILACS and PubMed/MEDLINE. Human observational and interventional studies that evaluated the following parameters were included: clinical attachment loss (CAL), probing pocket depth (PPD), bleeding on probing (BOP), radiographic bone loss (RBL) or osseointegration. Results Initial search retrieved 1,282 non‐duplicated articles. Fifteen studies were selected after inclusion criteria were applied. All studies were performed in postmenopausal women. Mean differences for PPD reduction ranged from 0.02 to 0.2 mm in HRT‐positive patients; mean CAL gain −0.18 to 0.54 mm; mean RBL reduction −0.87 to 0.15 mm; and mean BOP reduction 9%‐30.3%. Failure rate of dental implants increased −5.5% to 11.21% when HRT was used. Conclusions Very low but consistent evidence suggests a reduction in BOP and no impact on RBL in postmenopausal women receiving HRT. There are inconsistent reports that suggest that HRT in postmenopausal women: (a) improves or does not impact PPD reduction and CAL gain; and (b) does not impact or increase implant loss. In summary, there is no evidence to support HRT prescription for either men or women for periodontal/implant placement purposes.

show abstract

Endocrinology of the Menopause

Cited by 138 publications

References 93 publications

Hormone Examination in Menopause

Hormone Examination in Menopause

Menopause and Rheumatic Disease

Sex hormone replacement therapy in periodontology—A systematic review

Contact Info

Product

Resources

About